ResMed Publishes Q1 FY2027 Earnings Call Transcript
Bitget2026/10/30 06:11- ResMed's Oct. 29, 2026, Q1 fiscal 2027 earnings call featured CEO Michael J. Farrell, CFO Aaron Bloomer and investor-relations chief Sallilyn Schwartz.
- Quarterly revenue reached $1.4 billion; non-GAAP diluted earnings per share rose 14% to $2.91.
- Management maintained full-year revenue guidance of $5.75 billion-$5.85 billion; non-GAAP earnings per share remain projected at $12-$12.25.
- Core constant-currency revenue growth guidance remains 5%-7%, with Bloomer calling the midpoint most likely as France's fleet-renewal benefit fades.
- Non-GAAP gross margin reached 62.5%; deferred Indiana expansion costs create an expected 30-basis-point sequential headwind in Q2.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Despite financing pressure, outstanding execution prevails; Citi maintains “Buy” rating on CoreWeave (CRWV.US) with a price target raised to $128.
Citi stated in a research report that CoreWeave has significantly outperformed expectations in terms of revenue, capacity, pricing, and profitability, demonstrating "outstanding execution within controllable range." Based on this, Citi maintains its "Buy/High Risk" rating and sets a target price of $128.
TSMC (TSM.US) personally invests in AI: spends $1 billion to acquire shares in Anthropic and OpenAI, entering the trillion-dollar IPO high-stakes arena
TSMC plans to invest up to $1 billion in both Anthropic and OpenAI, allocating $500 million to each company. The company's annual revenue is expected to increase by approximately 44%, with strong demand for AI chips continuing.
Correction to Barrick Article
Peter Brandt Sees 30-Year Yield at 7%. Would Bitcoin and Stocks Survive?
Crypto prices
More
